Clinical Trial UCI-16-63

Title

A Phase III Randomized, Open-label Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib versus Sunitinib Monotherapy as a First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-426)

Principal Investigator

John P Fruehauf

Details

Learn More

For more information about cancer clinical trials at the Chao Family Comprehensive Cancer Center, please call toll-free: 877.UC.STUDY (877.827.8839) or email ucstudy@uci.edu